Taxoprexin® Treatment for Advanced Primary Cancers of the Liver
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To evaluate objective response rate and duration of response to weekly Taxoprexin®.
To evaluate the safety profile of weekly Taxoprexin® in this patient population.
To evaluate overall survival in the same patient population.
To evaluate time to disease progression, and the time to treatment failure in patients with
primary liver cancer being treated with weekly Taxoprexin® Injection.
To explore the trough and peak blood levels of Taxoprexin® and paclitaxel in these patients.